Home › NDC Lookup › Ingredients › Oxybutynin › 00023-9637-04
Oxytrol for Women Oxybutynin 3.9 mg/d Patch — NDC 00023-9637-04 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Oxytrol for Women Oxybutynin 3.9 mg/d Patch — NDC 0023-9637-04 (Billing 00023-9637-04)

by Allergan, Inc. · 16 PATCH in 1 CARTON / 4 d in 1 PATCH

This is a package of Oxytrol for Women Oxybutynin 3.9 mg/d Patch from Allergan, Inc., marketed since Jan 2016 and currently FDA-listed; retail pharmacies pay about $2.74 per unit (NADAC).

NDC 00023-9637-04
🏷️ FDA NDC (as labeled) 0023-9637-04 billing pads the labeler segment with a zero
This package
Contains4 d in 1 patch Cost per ea$2.74 NADAC Per package$43.88 / 16 patch Pack sizes2 compare ↓
Product page 00023-9637-08 Also comes in: 32 patches 0023-9637-08
OTC Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0023-9637-04 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0023 labeler · 9637 product · 04 package
Package marketed since
Jan 1, 2016
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0023963704 7
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0023-9637-04
Product NDC 0023-9637
11-digit billing NDC 00023963704
NCPDP billing unit EA — each (per item)
RxCUI 403799, 404448
UNII K9P6MC7092
Application # NDA202211
SPL Set ID 8cdc5b4d-ff8d-4010-97d7-313422a0b868
Established class (EPC) Cholinergic Muscarinic Antagonist
Mechanism of action Cholinergic Muscarinic Antagonists
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2016-01-01
Route TRANSDERMAL
Dosage form PATCH
Substance OXYBUTYNIN

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 54100045008720
GPI class Oxytrol For Women
GCN Seq No 071392
GCN 35162
HICL code 025056
Ingredient (HICL) Oxybutynin
HIC1 code R
Therapeutic class — broad (HIC1) Kidney/Urinary Tract
HIC2 code R1
Therapeutic class — intermediate (HIC2) Affect Primarily Kidneys/Urinary Tract
HIC3 code R1A
Therapeutic class — specific (HIC3) Urinary Tract Antispasmodic/Antiincontinence Agent
AHFS code 86:12.04.00
AHFS class Antimuscarinics
FDB label name OXYTROL FOR WOMEN 3.9 MG/24HR
FDB brand name Oxytrol For Women
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 071392
  • GCN: 35162
  • GPI-14 (Medi-Span): 54100045008720
  • HICL (First Databank): 025056
  • AHFS class code: 86:12.04.00
  • RxCUI (RxNorm): 403799
Why two NDCs? The FDA registers this code as 0023-9637-04 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00023-9637-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Cholinergic Muscarinic Antagonist class.

Pharmacologic class Cholinergic Muscarinic Antagonist
Drug family (ATC) Drugs for urinary frequency and incontinence
How it works Cholinergic Muscarinic Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name OXYTROL FOR WOMEN 3.9 MG/24HR Ingredient Oxybutynin
📖 What it is MedlinePlus · NLM

Oxybutynin transdermal patches are used to treat an overactive bladder (a bladder condition that causes sudden urges to urinate that may be hard to control). Oxybutynin is in a class of medications called antimuscarinics. It works by relaxing the bladder muscles.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Oxybutynin calms down an overactive bladder by relaxing the bladder muscle and reducing those sudden, hard-to-ignore urges to go. Over time, most people find they have fewer urgent...
  • What exactly is oxybutynin supposed to do for me?
  • Yes, dry mouth is the most common side effect of oxybutynin — and it's more noticeable with the immediate-release tablets than the extended-release form. Sipping water throughout t...
  • My mouth is incredibly dry since starting this — is that normal?
📖 Read our full Oxybutynin guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $2.742 $43.88 / 16 patch
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Oct 2021 Nov 2025 Apr 2026 Sep 2026 $2.750 $2.568
▲ Up 7% over the last 13 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00023-9637-04 You're viewing this 16 PATCH in 1 CARTON / 4 d in 1 PATCH $2.74 / ea $43.88 2016-01-01 — Active
00023-9637-08 0023-9637-08 Main listing 32 PATCH in 1 CARTON / 4 d in 1 PATCH $2.74 / ea $87.76 2019-10-01 — Active

This pack has the lowest per-ea cost of the 2 priced pack sizes ($2.74 NADAC).

This pack shows little to no recent Medicaid volume — a different pack size carries most fills. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 16 patch in 1 carton / 4 d in 1 patch.
What NDC number is used to bill for this package of Oxytrol for Women Oxybutynin 3.9 mg/d Patch?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Oxytrol for Women 3.9 mg/dthis 00023-9637-04 Allergan, 16 patches $2.742 — Availability likely —
Oxytrol 3.9 mg/d 00023-6153-08 Allergan, 8 patches $81.286 — Availability likely +2864%
About this product: this is the brand-name version. Some generic versions are approved by the FDA, but we could not confirm current pharmacy availability from our pricing/market data.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2016
On the market since
Jan 2016
📍
2026
Currently FDA-listed
10 years listed
🔒
·
Generic approved (availability unconfirmed)
see note
🔒Generic approved by FDA, but pharmacy availability is not confirmed

The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Oxybutynin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII XHX3C3X673
    Triacetin is a clear, oily liquid made from glycerin and acetic acid. It works as a plasticizer and solvent in medicines, helping soften coatings and improve how liquids mix together in formulations.

1 inactive ingredient listed in the exact product block matched to this NDC.

The official label also statesacrylic adhesive, polyester/ethylene-vinyl acetate film, siliconized polyester film, and triacetin

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAllergan, Inc.
Application holderABBVIE
FDA applicationNDA202211 (NDA)
Labeler code00023
First marketedJan 2016
Product typeHuman Otc Drug
Portfolio188 products on file

More NDCs from Allergan, Inc. labeler code 00023

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 Ask a Doctor Before Use If 📄 Ask a Doctor or Pharmacist Before Use If 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Other Information 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 87 words ▾

Use treats overactive bladder in women you may be suffering from overactive bladder if you have had 2 or more of the following symptoms for at least 3 months: ○ urinary frequency (the need to urinate more often than usual; typically more than 8 times in 24 hours) ○ urinary urgency (a strong need to urinate right away) ○ urge incontinence (leaking or wetting yourself if you cannot control the urge to urinate) non-drug therapies may also help you (see the consumer information leaflet inside the package)

⏱️ Dosage and Administration 212 words ▾

Directions women 18 years of age and older: How to use the patch: open 1 pouch and apply patch immediately to a clean, dry and smooth area of skin on your abdomen, hips or buttocks. Do not put the patch on oily, damaged (cut or scraped), or irritated (rashes) skin. Do not put the patch on skin with oils, lotions or powders because that could keep the patch from sticking to your skin. wear patch under clothing, do not expose the patch to sunlight do not cut the patch into smaller pieces wear only 1 patch at a time for 4 days in a row after 4 days, remove the used patch and apply a new one change the patch every 4 days for as long as you use this product each time you put on a new patch, change the place where you put it (i.e., abdomen, hips or buttocks) if a patch falls off and you cannot press it back onto your skin, use a new patch How to dispose of a used patch: when you take off a used patch, fold it in half with the sticky sides together throw it away so that it cannot be worn or swallowed by another person, especially a child, or a pet

⚠️ Warnings ~2 min read ▾

Warnings For external use only Frequent urination can also be caused by: urinary tract infections (UTI) diabetes early pregnancy other more serious conditions If you think you might have one of these conditions, it is important to see your doctor before use. Sleepiness, dizziness, confusion, and blurry vision may occur. Do not drive or operate machinery until you know how the patch affects you.

Do not use if you have any of these symptoms, which could be the sign of a UTI or other serious condition. See your doctor as soon as possible if you have: ○ pain or burning when urinating. These symptoms may also be accompanied by a fever or chills. ○ blood in your urine ○ unexplained lower back or side pain ○ urine that is cloudy, or foul-smelling ○ are male.

Your symptoms may be due to a more serious condition. ○ are under the age of 18. It is not known if it works or is safe in children. ○ only experience accidental urine loss when you cough, sneeze or laugh, you may have stress incontinence. This product will not work for that condition. ○ have been told by a doctor you have urinary retention (are not able to empty your bladder) ○ have been told by a doctor you have gastric retention (your stomach empties slowly after a meal) ○ have glaucoma ○ are allergic to oxybutynin Ask a doctor before use if you have symptoms of diabetes, such as: ○ excessive thirst ○ extreme hunger unexplained weight loss liver or kidney disease Ask a doctor or pharmacist before use if you are taking a prescription medication for overactive bladder taking any drugs that may cause sleepiness, dizziness, dry mouth, constipation or blurred vision taking certain antibiotics (for example, erythromycin, clarithromycin) or prescription antifungals (for example, ketoconazole, itraconazole) When using this product you may have itching, rash or redness where the patch was placed drinking alcohol may increase sleepiness Stop use and ask a doctor if you are not able to empty your bladder (urinary retention) condition worsens, or if new symptoms appear condition does not improve after 2 weeks of use you have an allergic reaction to this product you have severe redness, itchiness or blistering at the site of application If pregnant or breastfeeding, ask a health professional before use.

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

🧪 Active Ingredient 10 words ▾

Active ingredient (in each patch [transdermal system]) Oxybutynin 3.9 mg/day

🧪 Inactive Ingredients 12 words ▾

Inactive ingredients acrylic adhesive, polyester/ethylene-vinyl acetate film, siliconized polyester film, and triacetin

🎯 Purpose 4 words ▾

Purpose Overactive bladder treatment

📄 Do Not Use 169 words ▾

Do not use if you have any of these symptoms, which could be the sign of a UTI or other serious condition. See your doctor as soon as possible if you have: ○ pain or burning when urinating. These symptoms may also be accompanied by a fever or chills. ○ blood in your urine ○ unexplained lower back or side pain ○ urine that is cloudy, or foul-smelling ○ are male.

Your symptoms may be due to a more serious condition. ○ are under the age of 18. It is not known if it works or is safe in children. ○ only experience accidental urine loss when you cough, sneeze or laugh, you may have stress incontinence. This product will not work for that condition. ○ have been told by a doctor you have urinary retention (are not able to empty your bladder) ○ have been told by a doctor you have gastric retention (your stomach empties slowly after a meal) ○ have glaucoma ○ are allergic to oxybutynin

📄 Ask a Doctor Before Use If 26 words ▾

Ask a doctor before use if you have symptoms of diabetes, such as: ○ excessive thirst ○ extreme hunger unexplained weight loss liver or kidney disease

📄 Ask a Doctor or Pharmacist Before Use If 45 words ▾

Ask a doctor or pharmacist before use if you are taking a prescription medication for overactive bladder taking any drugs that may cause sleepiness, dizziness, dry mouth, constipation or blurred vision taking certain antibiotics (for example, erythromycin, clarithromycin) or prescription antifungals (for example, ketoconazole, itraconazole)

📄 When Using This Product 21 words ▾

When using this product you may have itching, rash or redness where the patch was placed drinking alcohol may increase sleepiness

📄 Stop Use and Ask a Doctor If 53 words ▾

Stop use and ask a doctor if you are not able to empty your bladder (urinary retention) condition worsens, or if new symptoms appear condition does not improve after 2 weeks of use you have an allergic reaction to this product you have severe redness, itchiness or blistering at the site of application

🤰 If Pregnant or Breast-Feeding 10 words ▾

If pregnant or breastfeeding, ask a health professional before use.

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📄 Other Information 37 words ▾

Other information product comes in individual sealed pouches, do not use if pouch is torn or opened store between 20° to 25°C (68° to 77°F) protect from moisture and humidity do not store outside the sealed pouch

📄 Questions or Comments 49 words ▾

Questions or comments? Call toll-free: 1-888-OXYTROL (1-888-699-8765) between 9:00 AM and 5:00 PM Eastern Standard Time, Monday through Friday © 2024 AbbVie. All rights reserved. Made in USA Distributed by: AbbVie Inc., North Chicago, IL 60064 OXYTROL and its design are trademarks of Allergan Sales, LLC, an AbbVie company.

📄 Package Label / Principal Display Panel 74 words ▾

PRINCIPAL DISPLAY PANEL NDC 0023-9637-04 Full Prescription Strength OXYBUTYNIN TRANSDERMAL SYSTEM 3.9 mg/day Overactive Bladder Treatment Oxytrol ® FOR WOMEN RELIEF FROM Overactive Bladder 1 Patch Treats for 4 Days/4 Nights 4 PATCHES (Transdermal Systems ) 16-Day Supply PRINCIPAL DISPLAY PANEL NDC 0023-9637-04 Full Prescription Strength OXYBUTYNIN TRANSDERMAL SYSTEM 3.9 mg/day Overactive Bladder Treatment Oxytrol® FOR WOMEN RELIEF FROM Overactive Bladder 1 Patch Treats for 4 Days/4 Nights 4 PATCHES (Transdermal Systems) 16-Day Supply

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
32 patches00023-9637-08 238 Rx · $7,400
16 patches this page00023-9637-04 No Medicaid data
Drug total (last 4 qtrs): 238 Rx · 2,000 units · $7,400 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Oxytrol (matched by generic name) — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Oxytrol. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$232K
Claims incl. refills
259
Beneficiaries
149
Spend / beneficiary
$1,557.02
Spend / claim
$895.74
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 00023-9537-05 · Allergan, 00023-9652-01 · Allergan, →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.